catalyst · primary record
Atezolizumab + Biospecimen Collection + Computed Tomography
Phase readout · 2027-04-30 · Extensive Stage Lung Small Cell Carcinoma
| Company | National Cancer Institute (NCI) |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P2/P3 primary completion · NCT04402788 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:51.047Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: National Cancer Institute (NCI):Atezolizumab + Biospecimen Collection + Computed Tomography:2027-04-30:P2/P3 primary completion · NCT04402788
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.